ライフサイエンスコーパス: CpG-ODN

1 CpG ODN enhanced expression of class I MHC and the costi

2 CpG ODN induced early killing of leukemia by innate immu

3 CpG ODN induced expression of CD80 similarly in B cells

4 CpG ODN markedly enhanced the expression and function of

5 CpG ODN treatment of lymphocyte-deficient C57BL/6-scid a

6 CpG ODN trigger immune cells to produce gamma interferon

7 CpG ODN type D were shown to improve clinical outcome in

8 CpG ODN was also co-encapsulated with p-Trp2 as an adjuv

9 CpG ODNs administered to mice efficiently inhibited Th2

10 CpG ODNs did not impair engraftment of TLR9(-/-) BM unle

11 CpG ODNs promoted BM rejection by ligation of donor BM,

12 CpG-ODN attenuation of angiogenesis, however, remains TL

13 CpG-ODN induced a more robust inflammatory response than

14 CpG-ODN pre-treated endothelial cells enhance macrophage

15 CpG-ODN prevented CLP-induced cardiac dysfunction, as ev

16 CpG-ODN prevents CLP-induced cardiac dysfunction, in par

17 CpG-ODN significantly attenuated CLP-induced myocardial

18 CpG-ODN stimulates macrophages and dendritic cells to se

19 CpG-ODN-induced intraocular inflammation was abrogated i

20 CpG-ODNs induced selective IDO expression by a minor pop

21 response against NP in mice immunized with a CpG ODN-containing NP-Ficoll vaccine but exhibited only

22 Here we have identified HMGB1 as a CpG-ODN-binding protein.

23 inhibition of ERK by U0126 in vivo abolished CpG-ODN attenuation of CLP-induced cardiac dysfunction.

24 Additionally, CpG-ODNs induce an M1 macrophage phenotype that restrict

25 y stable hapten analogue and a Th1 adjuvant (CpG ODN).

26 methylated CpG motifs as a vaccine adjuvant (CpG ODN).

27 Addition of the adjuvants CpG-ODN or Poly(I:C) preferentially amplified Teffs over

28 In addition, mice in remission after CpG ODN treatment were protected from leukemia rechallen

29 After CpG-ODN vaccination plus Treg depletion, 70% of young A2

30 By 6 hours after CpG-ODN administration, TLR9 mRNA was increased in the c

31 , or TLR9, but responded to the TLR9 agonist CpG ODN by production of IFNgamma.

32 dendritic cells (PDC) with the TLR9 agonist, CpG ODN 2216, triggered NK lysis of HIV-1-infected autol

33 Despite cell type preferences, all CpG-ODNs require the presence of TLR9 for activation.

34 ml), whereas cells stimulated with Ab alone, CpG ODN alone, or Ab and control ODN produced negligible

35 CpG-DNA or its synthetic analog CpG-ODN activates innate immunity through Toll-like rece

36 B-CLL cells treated with IL-21 and CpG ODN undergo apoptosis and are able to induce apoptos

37 nant NY-ESO-1 protein, Montanide ISA-51, and CpG ODN 7909, a potent stimulator of B cells and T helpe

38 CSF, serving as a DC enhancement factor, and CpG ODN, serving as a DC activating factor, into sponge-

39 er, co-administration of CpG ODN fma1555 and CpG ODN 1555 in this model increased the window for ther

40 spite a normal response to both anti-IgM and CpG ODN 1826.

41 accinated with HIV Gag protein/Montanide and CpG ODN or the TLR7/8 agonist had higher frequencies of

42 how that local treatment with Ad5-mTRAIL and CpG ODN can augment tumor antigen cross-presentation res

43 The controlled release of anti-PD1 and CpG ODN by CpG DNA-based "nano-cocoons" can induce consi

44 nvestigated whether a combination of pFL and CpG ODN as a nasal adjuvant for a pneumococcal surface p

45 tion with PspA plus a combination of pFL and CpG ODN elicited elevated levels of PspA-specific secret

46 ice given PspA plus a combination of pFL and CpG ODN showed protective immunity against nasal S. pneu

47 s of synergy between accessory cytokines and CpG-ODN in NK cells.

48 In contrast, LPS, MPLA, and CpG-ODN, but not poly(I:C), improved the host response t

49 ors was essential for IDO up-regulation, and CpG-ODNs induced selective activation of STAT-1 in CD19+

50 his study, we report the development of anti-CpG-ODN antibodies in 21 of 37 patients who received CpG

51 These data show that topically applied CpG-ODN induces intraocular inflammation owing to TLR9 a

52 e reveal that DEC-205 directly binds class B CpG ODN and enhances their uptake.

53 s identify an important receptor for class B CpG ODN and reveal a unique function for DEC-205.

54 -205 preferentially binds a specific class B CpG ODN that has been selected for human clinical trials

55 of CD11c(hi) DCs from WT, but not T-bet-/-, CpG ODN-treated donor mice.

56 his is the first report of synergism between CpG ODN and IL-2.

57 However, both CpG ODN and imiquimod also induced proinflammatory cytok

58 express both TLR9 and 4, and respond to both CpG ODN and LPS in vitro by differentiating into high af

59 nized CpG-ODN with different CpG motifs, but CpG-ODN with GACGTT or AACGTT had better activity to thi

60 e to infection was significantly enhanced by CpG ODN treatment and was associated with decreased para

61 tigated the antileukemia activity induced by CpG ODN in a transplantable syngeneic pre-B ALL model.

62 The CD4(+)CD25(+) T cells induced by CpG ODN-activated PDCs express forkhead transcription fa

63 ation that is required for CD80 induction by CpG ODN might explain the preservation of this response

64 atal immune system respond to stimulation by CpG ODN, thereby reducing host susceptibility to infecti

65 We show that pDCs activated by CpG-ODN promote NK cell cytotoxicity and interferon (IFN

66 Regulation of angiogenesis by CpG-ODN is pervasive and tissue non-specific.

67 Activation of these two TLRs by CpG-ODN occurred inside the cells and was modulated by U

68 The effects mediated by CpG-ODNs can therefore modulate both endothelial cells a

69 Type C CpG-ODNs combine features of both types A(D) and B(K) Cp

70 The results indicate that coadministering CpG ODN-PLG with AVA induces a stronger and faster immun

71 BL/6 mice were treated with CpG-ODN, control CpG-ODN (control-ODN), or inhibitory CpG-ODN (iCpG-ODN)

72 ity of lupus B cells to respond to type A(D) CpG-ODN stimulation is not due to differential TLR9 expr

73 cells from lupus mice responds to type A(D) CpG-ODN stimulation vigorously and directly with increas

74 Therefore, type A(D) CpG-ODNs may contribute to the lupus pathogenesis by ind

75 In mice, type A(D) CpG-ODNs primarily stimulate macrophages and dendritic c

76 R9 expression, but, despite this deficiency, CpG ODNs induce potent inhibitory effects on Th2 cytokin

77 e constitutively active ARF6 mutant enhanced CpG ODN-induced cytokine production.

78 Finally, CpG ODNs may correct deficient newborn response to polys

79 nd the animals in group 3 received the first CpG-ODN administration between the antigen treatments.

80 Following CpG-ODN treatment, CD19+ DCs acquired potent IDO-depende

81 sed by a variety of cells, is a receptor for CpG ODN.

82 hat plasmacytoid DCs (pDCs) are required for CpG ODN-mediated protection against lethal vaginal chall

83 the lesions, suggesting a potential role for CpG ODN in L. major treatment.

84 in the spleen express TLR9, the receptor for CpG ODNs, but lung DCs show no detectable expression in

85 a new and alternative signaling pathway for CpG-ODN in murine NK cells.

86 Furthermore, CpG-ODN stimulation in the presence of accessory cytokin

87 l)aminoethyl thiophosphate protecting group (CpG ODN fma1555) was prepared from phosphoramidites 1a-d

88 How CpG ODN are captured and delivered to the intracellular

89 However, CpG ODN delivered with MVA was able to substitute for CD

90 version to the well-studied immunomodulatory CpG ODN 1555 through thermolytic cleavage of the 2-(N-fo

91 ARF6 by dominant mutants and siRNA impaired CpG ODN-mediated responses, whereas cells expressing the

92 The impaired CpG-ODN-induced TNF-alpha production is GNP concentratio

93 n both plasma and peritoneal lavage fluid in CpG ODN-treated versus non-CpG ODN-treated rats 24 h aft

94 nose receptor 1 (MRC1; CD206) is involved in CpG ODN uptake and trafficking in wild-derived MOLF/Ei p

95 yeloperoxidase activity, was also reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CL

96 rial load in peritoneal fluid was reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CL

97 ecruitment of peripheral cells to the CNS in CpG-ODN-inoculated mice.

98 in untreated and IL-4-pretreated but not in CpG-ODN-pretreated cells.

99 olved in opsonin-independent phagocytosis in CpG-ODN-pretreated but not in IL-4-pretreated J774 cells

100 blood eosinophilia and airway remodeling in CpG-ODN-treated mice emphasized its usefulness as an imm

101 rimed with protective TLR ligands, including CpG-ODN, showed reduced plasma cytokines during P. aerug

102 d with CpG ODN but not GpC ODN had increased CpG ODN uptake due to CpG ODN-induced ARF6 activity.

103 control CpG-ODN (control-ODN), or inhibitory CpG-ODN (iCpG-ODN) 1 hour prior to cecal ligation and pu

104 The capacity of prophylactic intranasal CpG ODN to enhance survival does not require adaptive im

105 Fluorescein isothiocyanate-CpG-ODN rapidly penetrated the cornea and ocular media t

106 On the contrary, type B(K) CpG-ODNs are excellent B cell activators.

107 combine features of both types A(D) and B(K) CpG-ODNs.

108 CLPs from mice treated with the TLR9 ligand CpG ODN had little ability to generate CD19+ B lineage c

109 n with TLR7 ligand imiquimod and TLR9 ligand CpG ODN-2216 was also impaired in discordant patients ev

110 ivated by toll-like receptor (TLR)-9 ligand (CpG ODN) stimulation, and both expand and mature after F

111 lylactide-co-glycolide (PLG) microparticles (CpG ODN-PLG) to accelerate and boost the protective immu

112 In a different infectious model, CpG ODN 1555 prevented the death of Tacaribe-infected mi

113 herapeutic compounds evaluated in the model, CpG-ODN reduced body weight loss (to <6% on days 3-7 aft

114 ucleotide containing unmethylated CpG motif (CpG-ODN) and alanyl-glutamine in vivo and in vitro.

115 deoxynucleotide (ODN) containing CPG motifs (CpG ODN 7909) was found to protect BALB/c mice from lung

116 oligodeoxynucleotides containing CpG motifs (CpG ODN) enhance allogeneic T(h)1 responses and reduce l

117 ylated cytidyl guanosyl dinucleotide motifs (CpG ODN) are TLR9 ligands with attractive immunostimulat

118 oligodeoxynucleotides containing CpG motifs (CpG ODNs) is remarkably protective against otherwise let

119 s (ODNs) containing unmethylated CpG motifs (CpG ODNs) were shown to activate TLR9-bearing B cells, m

120 In contrast, neither CpG ODN nor LPS alone is sufficient to activate memory B

121 55 in water when compared to that of neutral CpG ODN fma1555 (homologous to 1).

122 Th2-polarizing factors (IL-4, M-CSF, and non-CpG ODN) decreased expression of MARCO on J774 macrophag

123 l lavage fluid in CpG ODN-treated versus non-CpG ODN-treated rats 24 h after CLP.

124 s also reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CLP.

125 id was reduced in CpG ODN-treated versus non-CpG ODN-treated rats after CLP.

126 ificant increase in DNA binding, whereas non-CpG ODN had no effect on DNA binding.

127 Both CpG and non-CpG ODNs directly costimulate mouse and human CD4(+) T c

128 ergistic induction of beta-chemokines by non-CpG-ODN was phosphorothioate (PS) chemistry dependent an

129 We have examined combinations of CpG- or non-CpG-ODN and GM-CSF for effects on the production of chem

130 in human primary monocytes when CpG- or non-CpG-ODN was combined with GM-CSF, but not with IL-4 or I

131 DCs is required for the adjuvant activity of CpG ODN in infection, revealing its vital role in innate

132 Addition of CpG ODN increased the CD8(+) response but not the Ab res

133 We found that addition of CpG ODN to modified vaccinia Ankara (MVA) markedly impro

134 further increased 5-fold by the addition of CpG ODN, compared with the levels in mice in the control

135 establish that intranasal administration of CpG ODN 1 day prior to lethal pulmonary exposure to Y. p

136 Moreover, co-administration of CpG ODN fma1555 and CpG ODN 1555 in this model increased

137 Administration of CpG ODN fma1555 three days before infection resulted in

138 Local intradermal administration of CpG ODN fma1555 was as effective as that of CpG ODN 1555

139 human primates showed that administration of CpG ODN type D (also known as type A) at the site of inf

140 Peripheral administration of CpG ODN, both before and after the development of CAA, n

141 amphiphile-CpG, an albumin-binding analog of CpG ODN, following systemic administration 3days after t

142 ting the potential clinical applicability of CpG ODN.

143 This work examines the capacity of CpG ODN to stimulate a protective immune response in new

144 s achieved with much lower concentrations of CpG ODN than optimal induction of proliferation.

145 urrent studies indicate that the delivery of CpG ODN directly into the tumor bed reduces the immunosu

146 D27, indicating that intranasal delivery of CpG ODN has systemic impacts.

147 To further the development of CpG ODN as a novel ALL therapy, we investigated the anti

148 e first time a protective adjuvant effect of CpG ODN for a live viral vector vaccine that may overcom

149 Although the protective effect of CpG ODN in adult mice was well established, its effectiv

150 The effect of CpG ODN is dependent on activation of p38 MAPK.

151 However, the effect of CpG ODN treatment on parasite morphology was not as mark

152 ts demonstrated that the adjuvant effects of CpG ODN and CTLA-4 blockades were CD8 dependent.

153 Little is known about the effects of CpG ODN on human PDC-mediated T cell priming.

154 Human NK cells cultured in the presence of CpG ODN plus immobilized IgG or Ab-coated tumor cells se

155 udy, we evaluated the therapeutic profile of CpG ODN in a triple transgenic mouse model, Tg-SwDI, wit

156 The immunostimulatory properties of CpG ODN fma1555 were evaluated in two in vivo assays, on

157 s required for downstream ARF6 regulation of CpG ODN uptake.

158 is the significant increase in solubility of CpG ODN psb1555 and CpG pob1555 in water when compared t

159 eta were undetectable in the supernatants of CpG ODN-stimulated PDC cultures.

160 orally and spatially controlled targeting of CpG ODN to pDCs and epithelial cells can potentially max

161 CpG ODN fma1555 was as effective as that of CpG ODN 1555 in reducing the size of Leishmania lesions

162 These findings provide new understanding of CpG ODN-mediated antitumor effects and support for the d

163 gnaling by regulating the cellular uptake of CpG ODN.

164 ent of clinical studies to assess the use of CpG ODN types D/A as immunoprotective and therapeutic ag

165 al information for potential clinical use of CpG ODN.

166 Application of CpG ODNs in HIV disease for adjuvant or immunoregulatory

167 Complete conversion of CpG ODNs hbu1555, psb1555, and pob1555 to CpG ODN 1555 (

168 -bet in mediating the protective function of CpG ODNs.

169 ides a molecular basis for the activities of CpG-ODN in fish.

170 vely mediate the antimicrobial activities of CpG-ODN.

171 The combination of CpG-ODN and anti-CCL1 treatments induced complete reject

172 atory indicate that intratumoral delivery of CpG-ODN strongly reduces the levels of Tregs within the

173 that only intratumoral (i.t.) injections of CpG-ODN induce an antitumor response in neu mice.

174 Following intratumoral injections of CpG-ODN, approximately 30% of young A2xneu mice rejected

175 iates the endocytosis and internalization of CpG-ODN by mouse bone marrow-derived macrophages and dir

176 R) 9 and TLR21 are the cellular receptors of CpG-ODN in mammals and chickens, respectively.

177 The ability of CpG-ODNs to induce both stimulatory and regulatory respo

178 findings highlight potential applications of CpG-ODNs and downstream molecules as antiinflammatory ag

179 racellular HMGB1 accelerates the delivery of CpG-ODNs to its receptor, leading to a TLR9-dependent au

180 agents but may complicate therapeutic use of CpG-ODNs to stimulate antitumor immunity in cancer patie

181 CpG oligodeoxynucleotide (CpG ODN) cellular uptake into endosomes, the rate-limiti

182 immunostimulatory CpG oligodeoxynucleotide (CpG ODN) was combined with Ad5-mTRAIL.

183 hylated CpG-containing oligodeoxynucleotide (CpG-ODN) restored IgG anti-PPS14 responses to young adul

184 a CpG motif-containing oligodeoxynucleotide (CpG-ODN), IL-12, and GM-CSF) increased, whereas Th2-pola

185 rly and respond to CpG oligodeoxynucleotide (CpG-ODN) by producing IFN-gamma and GM-CSF.

186 ined the effect of CpG oligodeoxynucleotide (CpG-ODN), the TLR9 ligand, on polymicrobial sepsis-induc

187 R9) stimulation by CpG-oligodeoxynucleotide (CpG-ODN) was integrated into microbiome-gene expression

188 ne-phosphate-guanosine oligodeoxynucleotide (CpG-ODN) to induce neuroinflammation after intracerebrov

189 8) and CpG-containing oligodeoxynucleotides (CpG ODN) to mice, growth of the TRP-2-expressing B16F1 m

190 ligand (pFL) and CpG oligodeoxynucleotides (CpG ODN) as a combined nasal adjuvant elicited mucosal i

191 or a TLR9 ligand [CpG oligodeoxynucleotides (CpG ODN)] had significantly increased Gag-specific T hel

192 e phosphate guanosine oligodeoxynucleotides (CpG ODN), and boosted 12 wk later with a replication-def

193 born B lymphocytes to oligodeoxynucleotides (CpG ODN) led to up-regulation of TACI expression on newl

194 CpG-motif containing oligodeoxynucleotides (CpG ODNs) is preceded by agonist endocytosis and deliver

195 PD-1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relaps

196 sphorothioate-guanine oligodeoxynucleotides (CpG ODNs) are synthetic ODNs with unmethylated DNA seque

197 icient in binding CpG oligodeoxynucleotides (CpG-ODN), the microbial DNA mimetic sensed by toll-like

198 e-phosphate-guanosine oligodeoxynucleotides (CpG-ODN), to investigate the role of TLR9 in vascular pa

199 related synthetic CpG oligodeoxynucleotides (CpG-ODNs) play an important role in immune cell survival

200 CpG oligodeoxynucleotides (CpG-ODNs) stimulate innate and adaptive immunity by bind

201 CpG-oligodeoxynucleotides (CpG-ODNs) are potent immune stimuli currently under inve

202 hibition of TLR9 (CpG oligodeoxynucleotides; CpG-ODNs) signal in macrophages.

203 ls with CXCL13-coupled CpG oligonucleotides (CpG-ODN) can block cancer metastasis by inhibiting CD20(

204 th HIV Gag protein and the TLR7/8 agonist or CpG ODN.

205 djuvants [Bordetella pertussis toxin (PT) or CpG ODN or a squalene-based oil-in-water nanoemulsion (N

206 orating GM-CSF in combination with P(I:C) or CpG-ODN induced the complete regression of solid tumors

207 is, we found that pDCs activated by virus or CpG-ODN preferentially express the ligand for the glucoc

208 Vaccine formulations of peptide+CpG-ODN or Poly(I:C) induced selective production of pro

209 Identical TRP-2(180-188) plus CpG ODN vaccines given without IL-2 elicited a TRP-2(180

210 ded systemic IL-2 to the TRP-2(180-188) plus CpG ODN vaccines, growth of B16F1 was inhibited in a CD8

211 When we administered TRP-2(180-188) plus CpG ODN-containing vaccines with systemic IL-2, 18.2% of

212 s when IL-2 was added to TRP-2(180-188) plus CpG ODN-containing vaccines.

213 Peptide plus CpG ODN vaccines administered with IL-2 generated epitop

214 Mice receiving CpG ODN and HER2/neu-positive tumor cells treated with a

215 zebTLR9 broadly recognized CpG-ODN with different CpG motifs, but CpG-ODN with GACG

216 In this regard, CpG ODN show promise as immunoprotective agents and as v

217 Although in the spleen CpG ODNs induced IL-6, a key cytokine induced via TLR9-M

218 Surprisingly, certain so-called stimulatory CpG-ODNs strongly inhibited the effector phase of inflam

219 In engraftment studies, CpG ODNs promoted allogeneic donor bone marrow (BM) reje

220 Further, we noted that synthetic CpG-ODN requires backbone phosphorothioate but not TLR9

221 ntibodies cross-reacted with other synthetic CpG-ODNs but not with the DNA of mixed bacterial vaccine

222 animals in a TLR9-dependent manner and that CpG ODN treatment may influence the developmental life c

223 wledge, this is the first demonstration that CpG ODN induce a durable remission and ongoing immune-me

224 These findings indicate that CpG ODN can directly enhance the NK cell cytokine respon

225 in vitro observations, it was observed that CpG ODN could help augment the Ab response against NP in

226 Additional studies showed that CpG ODN uptake was increased in ARF6-activated cells but

227 Further studies showed that CpG ODN-treated microglia increased their capacity to en

228 We show that CpG ODNs markedly accelerated graft-versus-host disease

229 We demonstrate that CpG-ODN stimulates inflammation yet inhibits angiogenesi

230 In vitro experiments demonstrated that CpG-ODN promotes an association between TLR9 and Ras, re

231 Taken together, these results indicate that CpG-ODN-targeted therapy and depletion of T-regs optimal

232 Mechanistic investigations suggested that CpG-ODN upregulates low surface levels of 4-1BBL on tBre

233 To identify the gene responsible for the CpG ODN defect, we have performed genome-wide linkage an

234 Several features of the CpG ODN-induced maturation were diminished in monocytes

235 icated as at least a partial mediator of the CpG ODN-induced monocyte maturation.

236 The CpG-ODN binding function of DEC-205 is conserved between

237 Consistent with cytokine inhibition, the CpG-ODN-induced phosphorylation of NF-kappaB and JNK as

238 To target the CpG-ODN to the tumor site anywhere within the body, we c

239 The CpG-ODNs that activate both zebTLR9 and zebTLR21 were mo

240 All of these CpG ODN-mediated impacts, including the increased pulmon

241 Furthermore, these CpG-ODNs induce high surface IgM expression and promote

242 This CpG-ODN chaperone complex-promoted innate immunity confe

243 Even though CpG-ODN injections plus Treg depletion could rescue the

244 Thus, CpG-ODNs delivered systemically at relatively high doses

245 TLR9-CpG ODN ligation-induced apoptosis of B-CLL cells is con

246 GpC ODN had increased CpG ODN uptake due to CpG ODN-induced ARF6 activity.

247 R9 allele, R892W, which is hyporesponsive to CpG ODN and acts as a dominant-negative in a cellular mo

248 mouse strain, MOLF/Ei, are hyporesponsive to CpG ODN but are fully responsive to bacterial DNA, thus

249 of CpG ODNs hbu1555, psb1555, and pob1555 to CpG ODN 1555 (homologous to 2) occurred under elevated t

250 tic and stromal compartments must respond to CpG ODN via TLR9 and to type I IFNs through IFN-alphabet

251 Only TLR9-expressing NK cells responded to CpG ODN and Ab, because cytokine production was not obse

252 + NK cells secreted IFN-gamma in response to CpG ODN and Ab-coated tumor cells.

253 duced production of IFN-alpha in response to CpG ODN and reduced frequencies of plasmacytoid dendriti

254 ribute to diminished functional responses to CpG ODN in HIV disease.

255 In contrast, proliferation responses to CpG ODN were markedly impaired in both naive and memory

256 LPS was superior to CpG ODN in increasing the allostimulatory potential of l

257 of TLR signaling pathways was also linked to CpG-ODN responsive fibroblasts, OTU1341 (Prevotella), an

258 ntrast, zebTLR21 responded preferentially to CpG-ODN with GTCGTT motifs.

259 zebrafish TLRs are functional, responding to CpG-ODN but not to other TLR ligands.

260 of proinflammatory cytokines in response to CpG-ODN, although cells from aged mice secreted higher l

261 IL-6, IL-12, TNFalpha, and iNOS response to CpG-ODN.

262 stribution to early endosomes in response to CpG-ODN.

263 o restored corneal inflammatory responses to CpG-ODN.

264 g individuals with fibroblasts responsive to CpG-ODN stimulation.

265 s affected TLR9 translocation in response to CpG-ODNs and to phagosomes.

266 Unlike CpG-ODNs, the effects of GpC-ODN required TLR7/TRIF-medi

267 -dioxygenase (IDO) is induced following i.v. CpG-ODN administration to mice.

268 When CpG ODN are used as an adjuvant, mice deficient in DEC-2

269 caused HMGB1 release into the medium whereas CpG ODN failed to induce this response.

270 ch as IL-15 and IL-18) was required, whereas CpG-ODN or accessory cytokines alone did not induce IFN-

271 nes, reflecting endotoxin tolerance, whereas CpG-ODN-primed mice showed augmented cytokine production

272 irst study assessing the mechanisms by which CpG ODN can protect mice from a neurotropic viral infect

273 vide insight into a novel mechanism by which CpG ODN contribute to tumor regression, and they support

274 Pretreatment of naive B cells with CpG ODN also enabled presentation of tetanus toxoid to C

275 y of soluble TS recombinant Ag combined with CpG ODN induces both TS-specific CD4(+) and CD8(+) T cel

276 on induced by intranasal TS Ag combined with CpG ODN requires B cells, which, after treatment with Cp

277 8 binding and defective co-localization with CpG ODN.

278 BALB/c mice but not TACI knockout mice with CpG ODN containing (4-hydroxy-3-nitrophenyl)acetyl-Ficol

279 Furthermore, cells pretreated with CpG ODN but not GpC ODN had increased CpG ODN uptake due

280 Pretreatment with CpG ODN resulted in enhanced bacterial clearance in lung

281 Indeed, intranasal prophylaxis with CpG ODN provides significant protection against subcutan

282 Plaque tissue stimulation with CpG ODN, a Toll-like receptor (TLR) 9 ligand, increased

283 Newborns treated with CpG ODN are protected from lethal Listeria challenge and

284 Neonatal BALB/c mice treated with CpG ODN at the time of infection had reduced viral load

285 Mice were treated with CpG ODN starting 7 days after injection with leukemia to

286 ination substrate reporter mice treated with CpG ODN.

287 is occurred in TNFalpha-/- mice treated with CpG ODN.

288 equires B cells, which, after treatment with CpG ODN, have the ability to induce TS-specific CD8(+) T

289 ocytogenes infection by prior treatment with CpG ODN.

290 challenge within 1 week of vaccination with CpG ODN-PLG plus AVA, with the level of protection corre

291 Preexposure therapy with CpG ODNs may protect victims of a biological attack from

292 ation and puncture (CLP), and treatment with CpG ODNs reduced sepsis mortality from 80% to 15% during

293 tion of Listeria monocytogenes compared with CpG-ODN treatment alone.

294 nti-Her-2/neu monoclonal antibody (mAb) with CpG-ODN.

295 ne, while those in group 2 were treated with CpG-ODN 1 day before the first antigen immunization, and

296 Male C57BL/6 mice were treated with CpG-ODN, control CpG-ODN (control-ODN), or inhibitory Cp

297 Similarly, treatment with CpG-ODN also downregulated inflammatory cell infiltratio

298 of ongoing and planned clinical trials with CpG-ODNs.

299 Vaccines containing TRP-2(180-188) without CpG ODN did not cause epitope-specific tumor growth inhi

300 Vaccines containing TRP-2(180-188) without CpG ODN elicited TRP-2(180-188)-specific responses of 2.